Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.

Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC

Calcified tissue international1 Jul 1996Cited by 55 (Europe PMC)

PMID8661976DOI10.1007/s002239900076PepBankPUB-08661976

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, proximal femur bone loss rates did not significantly differ among daily calcitonin, thrice-weekly calcitonin, and placebo.
In plain wordsIn postmenopausal women, upper thigh bone loss rates were similar with both calcitonin schedules and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeProximal femur bone loss rates
Study
n = 117
Comparator
placebo and the other calcitonin schedule
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily or three times weekly · intranasal · 2 yearsAs given in this study (human).
Source sentences
Summary
Although the rates of bone loss in the proximal femur were not significantly different in the three groups, there were differences over time.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197604
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with reduced bone density, daily calcitonin preserved lumbar spine BMD versus placebo over two years.
In plain wordsIn postmenopausal women, daily calcitonin preserved spine bone density compared with placebo.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD versus placebo
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 2 yearsAs given in this study (human).
Measurements
P value
< 0.02
daily calcitonin versus placebo over 2 years
Source sentences
Summary
Compared with placebo, daily intranasal calcitonin resulted in no significant bone loss in the lumbar spine, as assessed by dual photon absorptiometry, over the 2-year study period (P < 0.02).
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197601
03HumanNon-randomized trialEfficacy outcome
In postmenopausal women, biochemical markers did not significantly change in any group, including both calcitonin schedules and placebo.
In plain wordsIn postmenopausal women, bone turnover markers did not significantly change with either calcitonin schedule or placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBiochemical bone turnover markers
Study
n = 117
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily or three times weekly · intranasal · 2 yearsAs given in this study (human).
Source sentences
Summary
No significant changes in biochemical markers were observed in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197607
04HumanNon-randomized trialSafety outcome
In postmenopausal women, calcitonin therapy was well tolerated with no significant treatment-related adverse events.
In plain wordsIn postmenopausal women, calcitonin was well tolerated without significant treatment-related adverse events.
Peptide
Calcitonin-salmon
Outcome
Not applicableTreatment-related adverse events
Study
n = 117
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily or three times weekly · intranasal · 2 yearsAs given in this study (human).
Source sentences
Summary
Therapy was well tolerated and there were no significant treatment-related adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197608
05HumanNon-randomized trialEfficacy outcome
In women more than 5 years postmenopause with the lowest baseline bone mass, daily calcitonin showed the greatest lumbar spine BMD response, reported as 3.1%.
In plain wordsWomen more than five years past menopause with the lowest bone mass showed the greatest spine density response to daily calcitonin.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD in late postmenopause
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 2 yearsAs given in this study (human).
Measurements
Lumbar spine BMD increase
3.1%
reported result
Source sentences
Summary
In this group, women more than 5 years postmenopause, with the lowest baseline bone mass, showed the greatest response to this treatment, with a total increase placebo in lumbar spine BMD of 3.1%.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197602
06HumanNon-randomized trialEfficacy outcome
In postmenopausal women, significant spinal bone loss occurred with thrice-weekly calcitonin, as it did with placebo.
In plain wordsIn postmenopausal women, spine bone density decreased with calcitonin three times weekly, as it did with placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseSpinal bone loss
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU three times weekly · intranasal · 2 yearsAs given in this study (human).
Measurements
P value
< 0.005
spinal bone loss in the placebo and thrice-weekly calcitonin groups
Source sentences
Summary
Significant spinal bone loss (P < 0.005) occurred in women receiving either placebo or thrice-weekly calcitonin.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197603
07HumanNon-randomized trialEfficacy outcome
In postmenopausal women, proximal femur bone loss was insignificant with daily calcitonin.
In plain wordsIn postmenopausal women, upper thigh bone loss was not significant with daily calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeProximal femur bone loss with daily treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 2 yearsAs given in this study (human).
Source sentences
Summary
Whereas bone loss in the daily calcitonin group was insignificant, women who received placebo or thrice-weekly calcitonin experienced significant bone loss (P < 0. 001).
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197605
08HumanNon-randomized trialEfficacy outcome
In postmenopausal women, significant proximal femur bone loss occurred with thrice-weekly calcitonin, as it did with placebo, whereas bone loss with daily calcitonin was insignificant.
In plain wordsIn postmenopausal women, upper thigh bone density decreased with calcitonin three times weekly, as it did with placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseProximal femur bone loss with thrice-weekly treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU three times weekly · intranasal · 2 yearsAs given in this study (human).
Source sentences
Summary
Whereas bone loss in the daily calcitonin group was insignificant, women who received placebo or thrice-weekly calcitonin experienced significant bone loss (P < 0. 001).
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years.
Summary · context
Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density.
Summary · context
They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo.
Report a problemFND-0866197606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.